Screener
Eligibility screening
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
51 US sites in AL, AZ, CA, CO +23
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.